Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This is a study of the efficacy and safety of Caelyx (pegylated liposomal doxorubicin) in
combination with carboplatin compared to the standard treatment of paclitaxel and carboplatin
in patients with epithelial ovarian cancer in late relapse (> 6 months).
Phase:
Phase 3
Details
Lead Sponsor:
ARCAGY/ GINECO GROUP
Collaborators:
AGO Study Group ANZGOG Arbeitsgemeinschaft Gynaekologische Onkologie Austria Australia New Zealand Gynaecological Oncology Group European Organisation for Research and Treatment of Cancer - EORTC NCIC Clinical Trials Group NSGO Schering-Plough